AI
| Followers | 843 |
| Posts | 122807 |
| Boards Moderated | 10 |
| Alias Born | 09/05/2002 |
Sunday, June 03, 2007 5:15:22 PM
Median Projected OS from Halabi Nomogram
in months, as reported by Dr. Gold on the recent
Bank of America webcast:
9901 is in green, 9902a is in blue, and 9902b is in orange.
Does it ring true that the projected survival is higher in the trial that allows symptomatic patients (9902b) than in the trials that were restricted to asymptomatic patients?
Why does this even matter? Because the high Halabi number for 9902b reported by Dr. Gold may be giving investors a false sense of hope about 9902b and thereby inflating the share price.
If this were Novartis instead of DNDN, I would give them the benefit of the doubt. But DNDN is not Novartis and hasn’t done anything to earn such trust.
in months, as reported by Dr. Gold on the recent
Bank of America webcast:
9901 is in green, 9902a is in blue, and 9902b is in orange.
Does it ring true that the projected survival is higher in the trial that allows symptomatic patients (9902b) than in the trials that were restricted to asymptomatic patients?
Why does this even matter? Because the high Halabi number for 9902b reported by Dr. Gold may be giving investors a false sense of hope about 9902b and thereby inflating the share price.
If this were Novartis instead of DNDN, I would give them the benefit of the doubt. But DNDN is not Novartis and hasn’t done anything to earn such trust.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
